Breathing in a Warming World: Uncovering the Environmental Impact of Respiratory Care
A Breath of Fresh Air, or a Cloud of Concern?
For many, climate change is an abstract concept, but for those with respiratory issues, it's a daily battle. From asthma attacks triggered by pollution to the long-term effects of wildfire smoke, the very air we breathe is under threat. And shockingly, the healthcare systems treating these conditions are part of the problem.
The Rising Tide of Respiratory Diseases
Climate extremes and poor air quality are like a double-edged sword, driving an increase in respiratory illnesses. Over 90% of the world's population breathes air that exceeds the World Health Organization's recommendations, and experts agree that environmental factors play a significant role in respiratory illness.
A Vicious Cycle Unveiled
Between 400 and 500 million adults worldwide are estimated to live with COPD, and over 250 million people battle asthma. The healthcare response to this burden has its own environmental cost. Health Care Without Harm estimates that global health services contribute about 5% of worldwide greenhouse gas emissions, a staggering figure that puts them among the world's top polluters.
Without intervention, healthcare emissions are projected to reach an alarming six gigatons annually by 2050, equivalent to adding over a billion cars to our roads.
Hospitals: The Hidden Polluters
Hospitals, especially intensive care units, are major contributors to this environmental impact. They consume vast amounts of energy, equipment, and single-use materials, making them highly polluting on a per-patient basis.
Respiratory specialists emphasize that early intervention by healthcare professionals is crucial. Early diagnosis and control of chronic diseases benefit not only patients but also reduce healthcare's carbon footprint.
Inhalers: A Dilemma Unveiled
Inhalers, commonly used to treat long-term lung diseases like COPD and asthma, embody this environmental dilemma. The most common type, pressurised metered-dose inhalers, use gas propellants with a high global warming potential. Recent estimates suggest these inhalers contribute significantly to greenhouse gas emissions, with the UK's National Health Service estimating they account for around 3% of its carbon footprint.
A Green Revolution in Respiratory Care
The good news is that efforts are underway to reduce this environmental impact. AstraZeneca's reformulated COPD inhaler, approved in the UK and EU, is a step towards greener respiratory care. It maintains the same active medicines but switches to a new propellant, reducing the inhaler's warming impact by nearly 99.9%.
Major pharmaceutical companies like Pfizer and Johnson & Johnson have also committed to reducing their emissions and environmental footprint. The concept of a "green patient" - a person whose chronic disease is well-controlled, avoiding high-carbon interventions - is gaining traction.
The Role of Regulation
For the pharmaceutical industry, technology is one part of the solution. The other is regulatory support for low-carbon options. Pablo Panella, senior vice-president for respiratory diseases at AstraZeneca, emphasizes the need for welcoming and facilitating regulations to encourage innovation and investment in environmentally friendly healthcare solutions.
A Call to Action
As we navigate the complexities of climate change, it's clear that respiratory care must be part of the solution. By addressing the environmental impact of healthcare, we can improve patient outcomes and reduce our carbon footprint. It's a win-win situation, but it requires action and innovation. So, let's breathe easy and work towards a greener, healthier future.
